Pulmonary blastoma with neuroendocrine differentiation in cell morules resembling neuroepithelial bodies

Chejfec, Gregorio; Cosnow, Iris; Gould, Nevenka S.; Husain, Aliya N.; Gould, Victor E.

doi:10.1111/j.1365-2559.1990.tb00740.x

Cited by 21 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the biological and immu nohistochemical diversity of the previously reported pul monary blastomas, in our case we tested all the immuno histochemical markers available in our laboratory. Histo logical and immunohistological findings in the tumorous tissue of our patient agree with those previously reported [1,3].…”

Section: Discussionsupporting

confidence: 92%

“…2], Pulmonary blastomas with the yolk sac and neuroendocrine differentiation and the malignant mela noma components are described [3,4], as well as a famil ial occurrence of the pulmonary blastoma and cystic nephroma among siblings [5], The pulmonary blastoma is a peripheral pulmonary lesion, has an unpredictable clini cal course and has been reported in children and in adults. The prognosis of a not curably resectable pulmonary blas toma is grave with a median survival of less than 1 vear [6],…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Blastoma with Fatal Hypercalcemia

Stančić¹,

Grbac

Ferenčić

et al. 1997

Respiration

View full text Add to dashboard Cite

We describe a 50-year-old, previously healthy male with metastatic pulmonary blastoma associated with hypercalcemic and hyperosmolar complications which caused his death after 5 days. The primary tumor consisted of epithelial [cytokeratin, β-hCG, CEA, neuron-specific enolase (NSE)-positive] and mesenchymal components (β-hCG, vimentin, NSE-positive, while the metastases had only a mesenchymal component.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Pulmonary Blastoma with Fatal Hypercalcemia

Stančić¹,

Grbac

Ferenčić

et al. 1997

Respiration

View full text Add to dashboard Cite

show abstract

“…In fact, the recognition of a NE phenotype is possible with immuno-histochemistry only, in the absence of light microscopical features of the NE origin. NE features may be recognised in all lung carcinoma types, most frequently in adenocarcinomas but also in squamous and large cell carcinomas or in sarcomatoid carcinomas/ blastomas [1,6,10,47]. The percentage of NE cells may range from 3 to 25%, either as single cells scattered among non-NE glandular or squamous neoplastic cells, or more rarely as small clusters of neoplastic cells admixed within the non-NE component.…”

Section: Ne Differentiation In Nsclcmentioning

confidence: 99%

Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data

et al. 2007

View full text Add to dashboard Cite

Neuroendocrine (NE) tumours of the lung include pure and mixed forms. In the former group, a continuum of lesions is recognised ranging from benign typical carcinoids to atypical carcinoids (having a low-grade behaviour, although often associated with regional and distant metastases), to the highly aggressive poorly differentiated carcinomas of the small and large cell types. In the mixed tumour group, the NE component is extensively represented in association with any of the non-small cell carcinoma subtypes (so-called combined carcinomas), or the NE component is restricted to a cell population scattered among adenocarcinoma cells (or more rarely within squamous or large cell carcinomas). The molecular profile of NE tumours has been widely investigated to identify features helpful for the diagnosis, prognosis and even therapy for this special lung tumour category. Specific chromosomal alterations, oncogene mutations and cell cycle molecule disregulation has been documented in NE tumours of the lung, as well as the expression of specific receptors or enzymes implicated in the response to biotherapies or to chemotherapeutic agents. The "molecular classification" of NE tumours should be integrated to morphology, for a better definition of the different histological types and a more appropriate selection of the therapeutic strategy.

show abstract

“…All had associated expression of NSE, human chorionic gonadotropin, serotonin and keratin. Somatostatin expression has also been described in a range of atypical pulmonary tumors including an adenocarcinoma with endometrioid features [55], an adenocarcinoma resembling fetal lung [56], a chondroma [57] and a blastoma [58]. We have evaluated a number of endocrine markers in serum and plasma and paraffin-embedded tissue sections of patients with NSCLC.…”

Section: Indirect Effectsmentioning

confidence: 99%

Somatostatin, Its Receptors and Analogs, in Lung Cancer

et al. 2001

View full text Add to dashboard Cite

Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women. Novel approaches to the management of lung cancer are urgently required. Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system. The peptide has numerous functions including inhibition of hormone release, immunomodulation and neurotransmission and is an endogenous inhibitor of cell proliferation and angiogenesis. Somatostatin and its analogs, including octreotide (SMS 201–995), somatuline (BIM 23014) and vapreotide (RC-160), act by binding to specific somatostatin receptors (SSTR) of which there are 5 principal subtypes, SSTR-1–5. Although elevated plasma somatostatin levels may be detected in 14–15% of patients, tumor cell expression appears rare. SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease. [¹¹¹In]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease. The potential role of radiolabelled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored. Somatostatin analog therapy results in significant growth inhibition of both SSTR-positive and SSTR-negative lung tumors in vivo. Recent work indicates that these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer.

show abstract

Pulmonary blastoma with neuroendocrine differentiation in cell morules resembling neuroepithelial bodies

Cited by 21 publications

References 20 publications

Pulmonary Blastoma with Fatal Hypercalcemia

Pulmonary Blastoma with Fatal Hypercalcemia

Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data

Somatostatin, Its Receptors and Analogs, in Lung Cancer

Contact Info

Product

Resources

About